Simotinib

Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities[1].

Product Specifications

CAS Number

[944258-89-3]

UNSPSC

12352005

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/simotinib.html

Purity

99.39

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=CC2=C(C(NC(C=C3)=CC(Cl)=C3F)=NC=N2)C=C1OCCN4CC5(CC5)C6(OCCO6)C4

Molecular Formula

C25H26ClFN4O4

Molecular Weight

500.95

References & Citations

[1]Hu XS, et al. Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial. Cancer Manag Res. 2019;11:4449-4459. Published 2019 May 13.